Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 through 70 years~2. Diagnosis of paediatric or adult SLE for \> 24 weeks and fulfilling ≥4 of the 11 American College of Rheumatology (ACR) classification criteria with at least one being:~   * Positive antinuclear antibody (ANA) or~  * Elevated anti-dsDNA antibodies or~  * anti-Smith (anti-Sm) antibodies~3. Interferon high test result~4. Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score ≥ 10~5. Currently receiving at least 1 of the following for treatment of SLE:~   • Oral prednisone or equivalent of ≤40 mg/day for a minimum of 2 weeks prior to signing the Informed Consent Form (ICF) and with stable dose for at least 2 weeks prior to randomization~   • Any of the following medications for at least 12 weeks prior to signing the ICF, and at a stable doses for at least 8 weeks prior to randomization: (i) Azathioprine ≤200 mg/day (ii) Antimalarials (eg, chloroquine, hydroxychloroquine, quinacrine) (iii) Mycophenolate mofetil ≤2 g/day or mycophenolic acid ≤1.44 g/day (iv) Oral, subcutaneous (SC), or intramuscular methotrexate ≤25 mg/week (v) Mizoribine ≤150 mg/day~6. Must not have signs of active or latent tuberculosis (TB).~7. Must not be pregnant or breastfeeding.~Exclusion Criteria:~1. Active severe or unstable neuropsychiatric SLE~2. Active severe SLE-driven renal disease~3. Any severe herpes infection at any time~4. Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or HIV infection.~5. Known history of a primary immunodeficiency (splenectomy, or any underlying condition predisposing for infection~6. Receipt of any investigation product within 4 weeks or 5 half -lives prior to signing of the ICF~7. History of cancer, apart from:~   * Squamous or basal cell carcinoma of the skin if successfully treated.~  * Cervical cancer in situ if successfully treated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Anifrolumab - Lower dose (Type: EXPERIMENTAL): 1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
- Placebo matching for lower dose of Anifrolumab (Type: PLACEBO_COMPARATOR): 1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
- Anifrolumab - Higher dose (Type: EXPERIMENTAL): 2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
- Placebo matching for higher dose of Anifrolumab (Type: PLACEBO_COMPARATOR): 2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50

Based on this trial design, predict the completion outcome and termination type (if applicable).